Cystic Fibrosis Lung Immunity: The Role of the Macrophage

Journal of Innate Immunity

Volumn 8, Issue 6, 2016, Pages 550-563

  Bruscia, Emanuela M ^a   Bonfield, Tracey L ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cystic fibrosis; Infection; Inflammation; Macrophages; Plasticity

Indexed keywords

ALPHA 1 ANTITRYPSIN; CD14 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NITRIC OXIDE SYNTHASE; SCAVENGER; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR;

ADAPTIVE IMMUNITY; CYSTIC FIBROSIS; HLA SYSTEM; HOMEOSTASIS; IMMUNITY; INFECTION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; PATHOPHYSIOLOGY; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; ANIMAL; GENETIC EPIGENESIS; GENETICS; HUMAN; IMMUNOLOGY; LUNG; LUNG ALVEOLUS MACROPHAGE;

ADAPTIVE IMMUNITY; ANIMALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; EPIGENESIS, GENETIC; HOMEOSTASIS; HUMANS; IMMUNITY, INNATE; INFECTION; INFLAMMATION; LUNG; MACROPHAGES, ALVEOLAR;

EID: 84976584948     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000446825     Document Type: Review

References (102)

1. Hussell T, Bell TJ: Alveolar macrophages: plasticity in a tissue-specific context. Nat Rev Immunol 2014; 14: 81-93.
2. Soehnlein O, Lindbom L: Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 2010; 10: 427-439.
3. Okabe Y, Medzhitov R: Tissue biology perspective on macrophages. Nat Immunol 2015; 17: 9-17.
4. Pandey S, Kawai T, Akira S: Microbial sensing by Toll-like receptors and intracellular nucleic acid sensors. Cold Spring Harb Perspect Biol 2015; 7:a016246.
5. Byrne AJ, Mathie SA, Gregory LG, Lloyd CM: Pulmonary macrophages: key players in the innate defence of the airways. Thorax 2015; 70: 1189-1196.
6. Wilson GB, Fudenberg HH: Does a primary host defense abnormality involving monocytes-macrophages underlie the pathogenesis of lung disease in cystic fibrosis? Med Hypotheses 1982; 8: 527-542.
7. Elborn JS, Norman D, Delamere FM, Shale DJ: In vitro tumor necrosis factor-alpha secretion by monocytes from patients with cystic fibrosis. Am J Respir Cell Mol Biol 1992; 6: 207-211.
8. Jones MM, Seilheimer DK, Pier GB, Rossen RD: Increased elastase secretion by peripheral blood monocytes in cystic fibrosis patients. Clin Exp Immunol 1990; 80: 344-349.
9. Wilson GB, Bahm VJ: Synthesis and secretion of cystic fibrosis ciliary dyskinesia substances by purified subpopulations of leukocytes. J Clin Invest 1980; 66: 1010-1019.
10. Yoshimura K, Nakamura H, Trapnell BC, Chu CS, Dalemans W, Pavirani A, Lecocq JP, Crystal RG: Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res 1991; 19: 5417-5423.
11. Thomassen MJ, Demko CA, Wood RE, Sherman JM: Phagocytosis of Pseudomonas aeruginosa by polymorphonuclear leukocytes and monocytes: effect of cystic fibrosis serum. Infect Immun 1982; 38: 802-805.
12. Doring G: The role of neutrophil elastase in chronic inflammation. Am J Respir Crit Care Med 1994; 150: S114-S117.
13. Hubeau C, Puchelle E, Gaillard D: Distinct pattern of immune cell population in the lung of human fetuses with cystic fibrosis. J Allergy Clin Immunol 2001; 108: 524-529.
14. Brennan S, Sly PD, Gangell CL, Sturges N, Winfield K, Wikstrom M, Gard S, Upham JW, Arest CF: Alveolar macrophages and CC chemokines are increased in children with cystic fibrosis. Eur Respir J 2009; 34: 655-661.
15. Regamey N, Tsartsali L, Hilliard TN, Fuchs O, Tan HL, Zhu J, Qiu YS, Alton EW, Jeffery PK, Bush A, Davies JC: Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Thorax 2012; 67: 164-170.
16. Hartl D, Griese M, Kappler M, Zissel G, Reinhardt D, Rebhan C, Schendel DJ, Krauss-Etschmann S: Pulmonary T(h)2 response in Pseudomonas aeruginosa-infected patients with cystic fibrosis. J Allergy Clin Immunol 2006; 117: 204-211.
17. Grasemann H, Schwiertz R, Matthiesen S, Racke K, Ratjen F: Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med 2005; 172: 1523-1528.
18. Murphy BS, Bush HM, Sundareshan V, Davis C, Hagadone J, Cory TJ, Hoy H, Hayes D Jr, Anstead MI, Feola DJ: Characterization of macrophage activation states in patients with cystic fibrosis. J Cyst Fibros 2010; 9: 314-322.
19. Jaecklin T, Duerr J, Huang H, Rafii M, Bear CE, Ratjen F, Pencharz P, Kavanagh BP, Mall MA, Grasemann H: Lung arginase expression and activity is increased in cystic fibrosis mouse models. J Appl Physiol (1985) 2014; 117: 284-288.
20. Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JB, Berger M: Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 1995; 13: 257-261.
21. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M: Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111-2118.
22. Wright AK, Rao S, Range S, Eder C, Hofer TP, Frankenberger M, Kobzik L, Brightling C, Grigg J, Ziegler-Heitbrock L: Pivotal advance: expansion of small sputum macrophages in CF: failure to express MARCO and mannose receptors. J Leukoc Biol 2009; 86: 479-489.
23. Meyer M, Huaux F, Gavilanes X, van den Brule S, Lebecque P, Lo Re S, Lison D, Scholte B, Wallemacq P, Leal T: Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. Am J Respir Cell Mol Biol 2009; 41: 590-602.
24. Di A, Brown ME, Deriy LV, Li C, Szeto FL, Chen Y, Huang P, Tong J, Naren AP, Bindokas V, Palfrey HC, Nelson DJ: CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006; 8: 933-944.
25. Andersson C, Zaman MM, Jones AB, Freedman SD: Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages. J Cyst Fibros 2008; 7: 68-78.
26. Bruscia EM, Zhang PX, Ferreira E, Caputo C, Emerson JW, Tuck D, Krause DS, Egan ME: Macrophages directly contribute to the exaggerated inflammatory response in cystic fibrosis transmembrane conductance regulator-/-mice. Am J Respir Cell Mol Biol 2009; 40: 295-304.
27. Keiser N, Gabdoulkhakova A, Riazanski V, Nelson D, Engelhardt J: Ferret alveolar macrophage function is dependent on CFTR. Pediatr Pulmonol 2014; 49: 278-279.
28. Sorio C, Buffelli M, Angiari C, Ettorre M, Johansson J, Vezzalini M, Viviani L, Ricciardi M, Verze G, Assael BM, Melotti P: Defective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosis. PLoS One 2011; 6:e22212.
29. van de Weert-van Leeuwen PB, van Meegen MA, Speirs JJ, Pals DJ, Rooijakkers SH, Van der Ent CK, Terheggen-Lagro SW, Arets HG, Beekman JM: Optimal complement-mediated phagocytosis of Pseudomonas aeruginosa by monocytes is CFTR-dependent. Am J Respir Cell Mol Biol 2013; 49: 463-470.
30. Bruscia EM, Zhang PX, Satoh A, Caputo C, Medzhitov R, Shenoy A, Egan ME, Krause DS: Abnormal trafficking and degradation of TLR4 underlie the elevated inflammatory response in cystic fibrosis. J Immunol 2011; 186: 6990-6998.
31. Shenoy A, Kopic S, Murek M, Caputo C, Geibel JP, Egan ME: Calcium-modulated chloride pathways contribute to chloride flux in murine CF-affected macrophages. Pediatr Res 2011; 70: 447-452.
32. Zaman MM, Gelrud A, Junaidi O, Regan MM, Warny M, Shea JC, Kelly C, O'Sullivan BP, Freedman SD: Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered. Clin Diagn Lab Immunol 2004; 11: 819-824.
33. Cory TJ, Birket SE, Murphy BS, Hayes D Jr, Anstead MI, Kanga JF, Kuhn RJ, Bush HM, Feola DJ: Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis. J Cyst Fibros 2014; 13: 164-171.
34. Bratcher PE, Rowe SM, Reeves G, Roberts T, Szul T, Harris WT, Tirouvanziam R, Gaggar A: Alterations in blood leukocytes of G551Dbearing cystic fibrosis patients undergoing treatment with ivacaftor. J Cyst Fibros 2016; 15: 67-73.
35. Sorio C, Montresor A, Bolomini-Vittori M, Caldrer S, Rossi B, Dusi S, Angiari S, Johansson JE, Vezzalini M, Leal T, Calcaterra E, Assael BM, Melotti P, Laudanna C: Mutations of cystic fibrosis transmembrane conductance regulator (CFTR) gene cause a monocyte-selective adhesion deficiency. Am J Respir Crit Care Med 2016; 193: 1123-1133.
36. Hisert KB, Schoenfelt KQ, Cooke G, Grogan B, Launspach JL, Gallagher CG, Donnelly SC, Welsh MJ, Singh PK, McKone EF, Becker L: Ivacaftor-induced proteomic changes suggest monocyte defects may contribute to the pathogenesis of cystic fibrosis. Am J Respir Cell Mol Biol 2016; 54: 594-597.
37. Cantin AM, Hartl D, Konstan MW, Chmiel JF: Inflammation in cystic fibrosis lung disease: pathogenesis and therapy. J Cyst Fibros 2015; 14: 419-430.
38. Saini Y, Dang H, Livraghi-Butrico A, Kelly EJ, Jones LC, O'Neal WK, Boucher RC: Gene expression in whole lung and pulmonary macrophages reflects the dynamic pathology associated with airway surface dehydration. BMC Genomics 2014; 15: 726.
39. Lubamba BA, Jones LC, O'Neal WK, Boucher RC, Ribeiro CM: X-box-binding protein 1 and innate immune responses of human cystic fibrosis alveolar macrophages. Am J Respir Crit Care Med 2015; 192: 1449-1461.
40. Kopp BT, Abdulrahman BA, Khweek AA, Kumar SB, Akhter A, Montione R, Tazi MF, Caution K, McCoy K, Amer AO: Exaggerated inflammatory responses mediated by Burkholderia cenocepacia in human macrophages derived from cystic fibrosis patients. Biochem Biophys Res Commun 2012; 424: 221-227.
41. Zhang PX, Cheng J, Zou S, D'Souza AD, Koff JL, Lu J, Lee PJ, Krause DS, Egan ME, Bruscia EM: Pharmacological modulation of the AKT/ microRNA-199a-5p/CAV1 pathway ameliorates cystic fibrosis lung hyper-inflammation. Nat Commun 2015; 6: 6221.
42. Bonfield TL, Hodges CA, Cotton CU, Drumm ML: Absence of the cystic fibrosis transmembrane regulator (CFTR) from myeloid-derived cells slows resolution of inflammation and infection. J Leukoc Biol 2012; 92: 1111-1122.
43. Zhang PX, Murray TS, Villella VR, Ferrari E, Esposito S, D'Souza A, Raia V, Maiuri L, Krause DS, Egan ME, Bruscia EM: Reduced caveolin-1 promotes hyperinflammation due to abnormal heme oxygenase-1 localization in lipopolysaccharide-challenged macrophages with dysfunctional cystic fibrosis transmembrane conductance regulator. J Immunol 2013; 190: 5196-5206.
44. Lamothe J, Valvano MA: Burkholderia cenocepacia-induced delay of acidification and phagolysosomal fusion in cystic fibrosis transmembrane conductance regulator (CFTR)-defective macrophages. Microbiology 2008; 154: 3825-3834.
45. Abdulrahman BA, Khweek AA, Akhter A, Caution K, Kotrange S, Abdelaziz DH, Newland C, Rosales-Reyes R, Kopp B, McCoy K, Montione R, Schlesinger LS, Gavrilin MA, Wewers MD, Valvano MA, Amer AO: Autophagy stimulation by rapamycin suppresses lung inflammation and infection by Burkholderia cenocepacia in a model of cystic fibrosis. Autophagy 2011; 7: 1359-1370.
46. Oceandy D, McMorran BJ, Smith SN, Schreiber R, Kunzelmann K, Alton EW, Hume DA, Wainwright BJ: Gene complementation of airway epithelium in the cystic fibrosis mouse is necessary and sufficient to correct the pathogen clearance and inflammatory abnormalities. Hum Mol Genet 2002; 11: 1059-1067.
47. Sturges NC, Wikstrom ME, Winfield KR, Gard SE, Brennan S, Sly PD, Upham JW: Monocytes from children with clinically stable cystic fibrosis show enhanced expression of Toll-like receptor 4. Pediatr Pulmonol 2010; 45: 883-889.
48. Simonin-Le Jeune K, Le Jeune A, Jouneau S, Belleguic C, Roux PF, Jaguin M, Dimanche-Boitre MT, Lecureur V, Leclercq C, Desrues B, Brinchault G, Gangneux JP, Martin-Chouly C: Impaired functions of macrophage from cystic fibrosis patients: CD11b, TLR-5 decrease and sCD14, inflammatory cytokines increase. PLoS One 2013; 8:e75667.
49. Kelly C, Canning P, Buchanan PJ, Williams MT, Brown V, Gruenert DC, Elborn JS, Ennis M, Schock BC: Toll-like receptor 4 is not targeted to the lysosome in cystic fibrosis airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2013; 304:L371-L382.
50. Rymut SM, Ivy T, Corey DA, Cotton CU, Burgess JD, Kelley TJ: Role of exchange protein activated by cAMP 1 in regulating rates of microtubule formation in cystic fibrosis epithelial cells. Am J Respir Cell Mol Biol 2015; 53: 853-862.
51. Hamai H, Keyserman F, Quittell LM, Worgall TS: Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling. J Lipid Res 2009; 50: 1101-1108.
52. Zhang Y, Li X, Grassme H, Doring G, Gulbins E: Alterations in ceramide concentration and pH determine the release of reactive oxygen species by CFTR-deficient macrophages on infection. J Immunol 2010; 184: 5104-5111.
53. White NM, Jiang D, Burgess JD, Bederman IR, Previs SF, Kelley TJ: Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2007; 292:L476-L486.
54. Gargalovic P, Dory L: Caveolins and macrophage lipid metabolism. J Lipid Res 2003; 44: 11-21.
55. Androulidaki A, Iliopoulos D, Arranz A, Doxaki C, Schworer S, Zacharioudaki V, Margioris AN, Tsichlis PN, Tsatsanis C: The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating micro-RNAs. Immunity 2009; 31: 220-231.
56. Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina D, Settembre C, Gavina M, Pulze L, Giardino I, Pettoello-Mantovani M, D'Apolito M, Guido S, Masliah E, Spencer B, Quaratino S, Raia V, Ballabio A, Maiuri L: Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol 2010; 12: 863-875.
57. Deretic V, Kimura T, Timmins G, Moseley P, Chauhan S, Mandell M: Immunologic manifestations of autophagy. J Clin Invest 2015; 125: 75-84.
58. Amer AO, Byrne BG, Swanson MS: Macrophages rapidly transfer pathogens from lipid raft vacuoles to autophagosomes. Autophagy 2005; 1: 53-58.
59. Bajmoczi M, Gadjeva M, Alper SL, Pier GB, Golan DE: Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa . Am J Physiol Cell Physiol 2009; 297:C263-C277.
60. Bessich JL, Nymon AB, Moulton LA, Dorman D, Ashare A: Low levels of insulin-like growth factor-1 contribute to alveolar macrophage dysfunction in cystic fibrosis. J Immunol 2013; 191: 378-385.
61. Fick RB Jr, Naegel GP, Matthay RA, Reynolds HY: Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay. J Clin Invest 1981; 68: 899-914.
62. Tosi MF, Zakem H, Berger M: Neutrophil elastase cleaves C3bi on opsonized Pseudomonas as well as CR1 on neutrophils to create a functionally important opsonin receptor mismatch. J Clin Invest 1990; 86: 300-308.
63. Barasch J, Kiss B, Prince A, Saiman L, Gruenert D, al-Awqati Q: Defective acidification of intracellular organelles in cystic fibrosis. Nature 1991; 352: 70-73.
64. Del Porto P, Cifani N, Guarnieri S, Di Domenico EG, Mariggio MA, Spadaro F, Guglietta S, Anile M, Venuta F, Quattrucci S, Ascenzioni F: Dysfunctional CFTR alters the bactericidal activity of human macrophages against Pseudomonas aeruginosa . PLoS One 2011; 6:e19970.
65. Haggie PM, Verkman AS: Cystic fibrosis transmembrane conductance regulator-independent phagosomal acidification in macrophages. J Biol Chem 2007; 282: 31422-31428.
66. Barriere H, Bagdany M, Bossard F, Okiyoneda T, Wojewodka G, Gruenert D, Radzioch D, Lukacs GL: Revisiting the role of cystic fibrosis transmembrane conductance regulator and counterion permeability in the pH regulation of endocytic organelles. Mol Biol Cell 2009; 20: 3125-3141.
67. Riazanski V, Gabdoulkhakova AG, Boynton LS, Eguchi RR, Deriy LV, Hogarth DK, Loaec N, Oumata N, Galons H, Brown ME, Shevchenko P, Gallan AJ, Yoo SG, Naren AP, Villereal ML, Beacham DW, Bindokas VP, Birnbaumer L, Meijer L, Nelson DJ: TRPC6 channel translocation into phagosomal membrane augments phagosomal function. Proc Natl Acad Sci USA 2015; 112:E6486-E6495.
68. Abdulrahman BA, Khweek AA, Akhter A, Caution K, Tazi M, Hassan H, Zhang Y, Rowland PD, Malhotra S, Aeffner F, Davis IC, Valvano MA, Amer AO: Depletion of the ubiquitin-binding adaptor molecule SQSTM1/p62 from macrophages harboring cftr ΔF508 mutation improves the delivery of Burkholderia cenocepacia to the autophagic machinery. J Biol Chem 2013; 288: 2049-2058.
69. Yuan K, Huang C, Fox J, Laturnus D, Carlson E, Zhang B, Yin Q, Gao H, Wu M: Autophagy plays an essential role in the clearance of Pseudomonas aeruginosa by alveolar macrophages. J Cell Sci 2012; 125: 507-515.
70. Schnaith A, Kashkar H, Leggio SA, Addicks K, Kronke M, Krut O: Staphylococcus aureus subvert autophagy for induction of caspaseindependent host cell death. J Biol Chem 2007; 282: 2695-2706.
71. Wegiel B, Larsen R, Gallo D, Chin BY, Harris C, Mannam P, Kaczmarek E, Lee PJ, Zuckerbraun BS, Flavell R, Soares MP, Otterbein LE: Macrophages sense and kill bacteria through carbon monoxide-dependent inflammasome activation. J Clin Invest 2014; 124: 4926-4940.
72. Vandivier RW, Henson PM, Douglas IS: Burying the dead: the impact of failed apoptotic cell removal (efferocytosis) on chronic inflammatory lung disease. Chest 2006; 129: 1673-1682.
73. Soleti R, Porro C, Martinez MC: Apoptotic process in cystic fibrosis cells. Apoptosis 2013; 18: 1029-1038.
74. McCubbrey AL, Curtis JL: Efferocytosis and lung disease. Chest 2013; 143: 1750-1757.
75. Croasdell A, Duffney PF, Kim N, Lacy SH, Sime PJ, Phipps RP: PPARγ and the innate immune system mediate the resolution of inflammation. PPAR Res 2015; 2015: 549691.
76. Bonfield TL, Farver CF, Barna BP, Malur A, Abraham S, Raychaudhuri B, Kavuru MS, Thomassen MJ: Peroxisome proliferator-activated receptor-gamma is deficient in alveolar macrophages from patients with alveolar proteinosis. Am J Respir Cell Mol Biol 2003; 29: 677-682.
77. Ollero M, Junaidi O, Zaman MM, Tzameli I, Ferrando AA, Andersson C, Blanco PG, Bialecki E, Freedman SD: Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/-mice. J Cell Physiol 2004; 200: 235-244.
78. Majai G, Sarang Z, Csomos K, Zahuczky G, Fesus L: PPARγ-dependent regulation of human macrophages in phagocytosis of apoptotic cells. Eur J Immunol 2007; 37: 1343-1354.
79. Roszer T: Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm 2015; 2015: 816460.
80. Vandivier RW, Fadok VA, Hoffmann PR, Bratton DL, Penvari C, Brown KK, Brain JD, Accurso FJ, Henson PM: Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis. J Clin Invest 2002; 109: 661-670.
81. Poon IK, Lucas CD, Rossi AG, Ravichandran KS: Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol 2014; 14: 166-180.
82. Garratt LW, Wright AK, Ranganathan SC, Grigg J, Sly PD; behalf of AC. Small macrophages are present in early childhood respiratory disease. J Cyst Fibros 2012; 11: 201-208.
83. Haq IJ, Gray MA, Garnett JP, Ward C, Brodlie M: Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets. Thorax 2016; 71: 284-287.
84. Bergougnoux A, Claustres M, De Sario A: Nasal epithelial cells: a tool to study DNA methylation in airway diseases. Epigenomics 2015; 7: 119-126.
85. Soltys J, Bonfield T, Chmiel J, Berger M: Functional IL-10 deficiency in the lung of cystic fibrosis (cftr-/-) and IL-10 knockout mice causes increased expression and function of B7 costimulatory molecules on alveolar macrophages. J Immunol 2002; 168: 1903-1910.
86. Mueller C, Braag SA, Keeler A, Hodges C, Drumm M, Flotte TR: Lack of cystic fibrosis transmembrane conductance regulator in CD3+ lymphocytes leads to aberrant cytokine secretion and hyperinflammatory adaptive immune responses. Am J Respir Cell Mol Biol 2011; 44: 922-929.
87. Collaco JM, Blackman SM, McGready J, Naughton KM, Cutting GR: Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. J Pediatr 2010; 157: 802-807. e1-e3.
88. Cutting GR: Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann NY Acad Sci 2010; 1214: 57-69.
89. Wright FA, Strug LJ, Doshi VK, Commander CW, Blackman SM, Sun L, Berthiaume Y, Cutler D, Cojocaru A, Collaco JM, Corey M, Dorfman R, Goddard K, Green D, Kent JW Jr, Lange EM, Lee S, Li W, Luo J, Mayhew GM, Naughton KM, Pace RG, Pare P, Rommens JM, Sandford A, Stonebraker JR, Sun W, Taylor C, Vanscoy LL, Zou F, Blangero J, Zielenski J, O'Neal WK, Drumm ML, Durie PR, Knowles MR, Cutting GR: Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 2011; 43: 539-546.
90. Weiler CA, Drumm ML: Genetic influences on cystic fibrosis lung disease severity. Front Pharmacol 2013; 4: 40.
91. Gaggar A, Chen J, Chmiel JF, Dorkin HL, Flume PA, Griffin R, Nichols D, Donaldson SH: Inhaled alpha1-proteinase inhibitor therapy in patients with cystic fibrosis. J Cyst Fibros 2016; 15: 227-233.
92. Chauhan B, Hutcheson PS, Slavin RG, Bellone CJ: MHC restriction in allergic bronchopulmonary aspergillosis. Front Biosci 2003; 8:s140-s148.
93. Jovanovic K, Siebeck M, Gropp R: The route to pathologies in chronic inflammatory diseases characterized by T helper type 2 immune cells. Clin Exp Immunol 2014; 178: 201-211.
94. Ohashi W, Hattori K, Hattori Y: Control of macrophage dynamics as a potential therapeutic approach for clinical disorders involving chronic inflammation. J Pharmacol Exp Ther 2015; 354: 240-250.
95. Liu X, Zhan Z, Li D, Xu L, Ma F, Zhang P, Yao H, Cao X: Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 2011; 12: 416-424.
96. Hofer TP, Frankenberger M, Heimbeck I, Burggraf D, Wjst M, Wright AK, Kerscher M, Nahrig S, Huber RM, Fischer R, Ziegler-Heitbrock L: Decreased expression of HLA-DQ and HLA-DR on cells of the monocytic lineage in cystic fibrosis. J Mol Med (Berl) 2014; 92: 1293-1304.
97. Barr TA, Gray M, Gray D: B cells: programmers of CD4 T cell responses. Infect Disord Drug Targets 2012; 12: 222-231.
98. Siegmann N, Worbs D, Effinger F, Bormann T, Gebhardt M, Ulrich M, Wermeling F, Muller-Hermelink E, Biedermann T, Tighe M, Edwards MJ, Caldwell C, Leadbetter E, Karlsson MC, Becker KA, Gulbins E, Doring G: Invariant natural killer T (iNKT) cells prevent autoimmunity, but induce pulmonary inflammation in cystic fibrosis. Cell Physiol Biochem 2014; 34: 56-70.
99. Bodas M, Vij N: The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential. Discov Med 2010; 9: 346-356.
100. Hector A, Schafer H, Poschel S, Fischer A, Fritzsching B, Ralhan A, Carevic M, Oz H, Zundel S, Hogardt M, Bakele M, Rieber N, Riethmueller J, Graepler-Mainka U, Stahl M, Bender A, Frick JS, Mall M, Hartl D: Regulatory T-cell impairment in cystic fibrosis patients with chronic Pseudomonas infection. Am J Respir Crit Care Med 2015; 191: 914-923.
101. Abu-El-Haija M, Ramachandran S, Meyerholz DK, Abu-El-Haija M, Griffin M, Giriyappa RL, Stoltz DA, Welsh MJ, McCray PB Jr, Uc A: Pancreatic damage in fetal and newborn cystic fibrosis pigs involves the activation of inflammatory and remodeling pathways. Am J Pathol 2012; 181: 499-507.
102. Munck A: Cystic fibrosis: evidence for gut inflammation. Int J Biochem Cell Biol 2014; 52: 180-183.